Integrative review about the lycopene effects in alzheimer disease

The Alzheimer Disease (AD) is a neurodegenerative disorder caused due the deposition 𝜷-amyloids plaques and neurofibrillary tangles. This condition triggers the neuroinflammation mediated by oxidative stress and cytokines. AD is highly prevalent among elderly people and has become a problem of public health. Although numerous attempts to develop a new drug to reverse this condition, until today there is no accessible medicine to successfully treat AD patients. The use of monoclonal antibodies is still too expensive for most of the population and the other medicines treat basically the symptoms. Searching for a financially viable solution, treatment who interfere in neuroinflammation seems to be the most accessible alternative. In this context, studies involving lycopene, an antioxidative compound, appear to be effective in AD treatment. However, the studies about the real role of lycopene is still controversial. To get a conclusion about the effectiveness of lycopene treatment in AD, this review aims to analyze studies involving the use of lycopene in different clinical and experimental studies. For this, we will use the platform Medical Subject Headings (MeSH) for selection terms of search and the databases as the PubMed, Web of Science, Scopus, Lilacs and Biblioteca Virtual em Saúde (BVS) for the selection of articles.